Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AYTU

AYTU - Aytu BioScience Inc Stock Price, Fair Value and News

$2.58-0.06 (-2.27%)
Market Closed

27/100

AYTU

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

27/100

AYTU

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AYTU Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AYTU Price Action

Last 7 days

2.4%

Last 30 days

13.7%

Last 90 days

12.2%

Trailing 12 Months

111.5%

AYTU RSI Chart

AYTU Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AYTU Valuation

Market Cap

27.7M

Price/Earnings (Trailing)

-1.13

Price/Sales (Trailing)

0.44

EV/EBITDA

-0.46

Price/Free Cashflow

-34.3

AYTU Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AYTU Fundamentals

AYTU Revenue

Revenue (TTM)

62.6M

Rev. Growth (Yr)

-6.51%

Rev. Growth (Qtr)

9.19%

AYTU Earnings

Earnings (TTM)

-24.4M

Earnings Growth (Yr)

-1.4K%

Earnings Growth (Qtr)

-638.63%

AYTU Profitability

Operating Margin

34.22%

EBT Margin

-38.70%

Return on Equity

-172.12%

Return on Assets

-20.04%

Free Cashflow Yield

-2.92%

AYTU Investor Care

Shares Dilution (1Y)

73.96%

Diluted EPS (TTM)

-1.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202565.8M66.4M63.7M62.6M
202467.3M65.2M63.9M61.4M
2023104.1M73.8M71.6M69.5M
202292.7M96.7M102.4M105.6M
202157.0M65.6M74.0M82.0M
202014.5M27.6M39.7M51.7M
20196.5M7.3M7.3M8.7M
20183.6M3.7M4.0M4.8M
20173.3M3.2M3.6M3.9M
20161.8M2.6M2.8M3.1M
2015110.2K261.8K721.6K1.2M
201431.7K45.3K76.7K92.5K
201333.6K41.8K18.1K0
20120017.2K25.4K
20110000
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About Aytu BioScience Inc

AYTU
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition, the company provides Karbinal ER, for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
 CEO
 WEBSITEhttps://aytubio.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES164

Aytu BioScience Inc Frequently Asked Questions

AYTU is the stock ticker symbol of Aytu BioScience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Aytu BioScience Inc is 27.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, AYTU's PE ratio (Price to Earnings) is -1.13 and Price to Sales (PS) ratio is 0.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AYTU PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Aytu BioScience Inc has provided -0.707 (multiply by 100 for percentage) rate of return.